Correlation Between Cannara Biotech and Pfizer

Can any of the company-specific risk be diversified away by investing in both Cannara Biotech and Pfizer at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cannara Biotech and Pfizer into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Cannara Biotech and Pfizer Inc CDR, you can compare the effects of market volatilities on Cannara Biotech and Pfizer and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cannara Biotech with a short position of Pfizer. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cannara Biotech and Pfizer.

Diversification Opportunities for Cannara Biotech and Pfizer

-0.04

Correlation Coefficient

Cannara Biotech  Pfizer

Good diversification

The 3 months correlation between Cannara and Pfizer is -0.04. Overlapping area represents the amount of risk that can be diversified away by holding Cannara Biotech and Pfizer Inc CDR in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Pfizer Inc CDR and Cannara Biotech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cannara Biotech are associated (or correlated) with Pfizer. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Pfizer Inc CDR has no effect on the direction of Cannara Biotech i.e., Cannara Biotech and Pfizer go up and down completely randomly.

Pair Corralation between Cannara Biotech and Pfizer

Assuming the 90 days trading horizon Cannara Biotech is expected to generate 4.28 times more return on investment than Pfizer. However, Cannara Biotech is 4.28 times more volatile than Pfizer Inc CDR. It trades about 0.25 of its potential returns per unit of risk. Pfizer Inc CDR is currently generating about 0.0 per unit of risk. If you would invest  70.00  in Cannara Biotech on December 24, 2024 and sell it today you would earn a total of  65.00  from holding Cannara Biotech or generate 92.86% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Cannara Biotech  vs.  Pfizer Inc CDR

Cannara Biotech

Risk-Adjusted Performance

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Cannara Biotech are ranked lower than 19 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Cannara Biotech showed solid returns over the last few months and may actually be approaching a breakup point.

Pfizer Inc CDR

Risk-Adjusted Performance

Very Weak

Over the last 90 days Pfizer Inc CDR has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Pfizer is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors.

Pair Trading with Cannara Biotech and Pfizer

The main advantage of trading using opposite Cannara Biotech and Pfizer positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cannara Biotech position performs unexpectedly, Pfizer can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pfizer will offset losses from the drop in Pfizer's long position.

The idea behind Cannara Biotech and Pfizer Inc CDR pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.